Eli Lilly is moving forward with plans to ask FDA to approve its latest experimental weight-loss drug, retatrutide, as a biologic after the GLP-1 showed substantial weight loss in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results